Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC-mAb in subjects with elevated lipoprotein (a)
NCT03320265Phase 2Terminated
- Sponsor
- Athera Biotechnologies AB
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Countries
- 2
01
Overview
A Phase 2 trial of ABR-001 in atherosclerosis, cardiovascular disease (CVD), sponsored by Athera Biotechnologies AB. Started Oct 2017; status: terminated.
02
Drugs
ABR-001
03
Conditions
atherosclerosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03320265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320265.